drugset
drugset / Trial / NCT04140695

Evaluating the Effects of Tradipitant vs. Placebo in Atopic Dermatitis (EPIONE2)

NCT04140695 ↗

Phase 3 Terminated 87 enrolled Vanda Pharmaceuticals
RandomizedParallel-groupQuadruple-blindTreatment

Summary

This is a multicenter, randomized, double-blind, placebo-controlled study to be conducted in the United States in subjects with atopic dermatitis.

Timeline

Start
2019-10-21
Primary completion
2020-10-14
Completion
2020-10-14

Drugs

EvaluationDrugModalityDoseRoute
Subject Tradipitant Small molecule — Oral

Indications

atopic eczema